Tag: DAPT

TCT 2019:Aspirin withdrawal after three months of dual antiplatelet therapy reduces...

Data from the TWILIGHT study demonstrate that, compared to ticagrelor plus aspirin, ticagrelor monotherapy reduces bleeding events without increasing the risk of death, myocardial...

ACC 2019: Less bleeding with one-month DAPT than standard therapy, with...

One-month dual antiplatelet therapy (DAPT) followed by 12 months of clopidogrel monotherapy leads to a greater reduction in bleeding events following percutaneous coronary intervention...

Patient recruitment reaches half-way point for global DAPT study

December marked a significant milestone for a major study into the use of short duration dual anti-platelet therapy (DAPT) in high bleeding risk patients...

Onyx One Clear study starts in USA and Japan

Medtronic has announced the start of the Onyx ONE Clear Study in the USA and Japan that will evaluate one-month dual antiplatelet therapy (DAPT)...

ESC 2018: Ticagrelor monotherapy approach does not challenge current DAPT approach

The GLOBAL LEADERS trial, simultaneously published in the Lancet and presented at the 2018 European Society of Cardiology (ESC) Congress (25–29 August, Munich, Germany),...

ESC 2018: DAPT score “not generalisable” to a nationwide population

A new study has found that the dual antiplatelet therapy (DAPT) score, which is recommended by both US and European guidelines, did not adequately...

Advantage of guided de-escalation of dual antiplatelet therapy seen in younger...

A pre-specified analysis of the TROPICAl-ACS study indicates that de-escalating dual antiplatelet therapy (DAPT), as guided by platelet function testing, after percutaneous coronary intervention...

ACC 2018: Short-term DAPT after PCI in acute coronary syndrome patients...

Data from the SMART-DATE study indicate that acute coronary syndrome patients who receive short-term (six months) dual antiplatelet therapy (DAPT) after percutaneous coronary intervention...

First patient enrolled in trial reviewing 28-day DAPT with Xience

The first patient has been enrolled in a clinical trial evaluating 28 days of dual antiplatelet therapy (DAPT) in patients at high risk of...

ESC 2017: Case builds for dropping aspirin from triple therapy in...

The RE-DUAL PCI trial indicates that dual therapy with the non-vitamin K antagonist oral anticoagulant dabigatran (Pradaxa, Boehringer Ingelheim)—and not aspirin—and a P2Y12 inhibitor...

Medtronic to undertake global randomised clinical trial of one-month DAPT in...

Medtronic has announced a global randomised clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT) in patients implanted with the Resolute Onyx drug-eluting...

EuroPCR 2017: Switching to clopidogrel after one month reduces bleeding without...

Data from the TOPIC (Timing of platelet inhibition after acute coronary syndrome) study indicate that swapping a new potent P2Y212 blocker for the less...

EuroPCR 2017: Greater risks with standard approach of dual antiplatelet therapy...

The ARTE study, which was simultaneously presented at EuroPCR (16–19 May, Paris, France) and published in JACC: Cardiovascular Interventions, indicates that dual antiplatelet therapy...

Risk of bleeding with aspirin in patients older than 75 is...

Peter Rothwell (University of Oxford, Oxford, UK) and colleagues report in The Lancet that long-term use of aspirin in people aged 75 or older...

First patient enrolled in new study of abbreviated DAPT post-stent in...

Gillian Jessurun (Treant Zorggroep, Scheper Hospital Emmen, The Netherlands) has enrolled the first patient in the investigator-initiated MASTER DAPT (Management of patients post bioresorbable...

ACC 2017: Dual anti-thrombotic approach has similar risk of bleeding to...

The GEMINI-ACS study, which was simultaneously presented at the 2017 scientific sessions of the American College of Cardiology (ACC; 17–19 March, Washington, DC, USA)...

“Simple five-item risk score” could be used to predict bleeding risk...

Francesco Costa (Swiss Cardiovascular Center Bern, Bern University Hospital, Bern, Switzerland) and others report in The Lancet that the PRECISE-DAPT score—“a simple five-item risk...

Physicians may be overlooking patients’ desire to avoid dual antiplatelet therapy...

A study, published in Catheterization and Cardiovascular Interventions, found that most patients undergoing coronary angiography believe that—following percutaneous coronary intervention (PCI)—avoiding dual antiplatelet therapy...

Procedural complexity should be considered when deciding duration of dual antiplatelet...

Gennaro Giustino and others report in the Journal of American College of Cardiology that—alongside other established risk factors—procedural complexity “is an important parameter to...

NICE recommends dual antiplatelet therapy with ticagrelor and aspirin

The National Institute of Health and Care Excellence (NICE) has published a final appraisal determination that states dual antiplatelet therapy with ticagrelor 60mg (Brilique,...

ESC 2016: Short-term DAPT is feasible with Nobori biodegradable polymer stent

The NIPPON (Nobori dual antiplatelet therapy as appropriate duration) study, presented in a hotline session at the ESC today, indicates that in patients undergoing...